Starting and titrating strong opioids

01Purpose and principlesWhat the treatment does and how it fits into care.

Starting a strong opioid is a prescribing process rather than a single prescription. Confirm pain mechanism, current analgesia and goals; calculate total prior opioid exposure; check swallowing, cognition, renal and hepatic function; identify interacting sedatives; and decide who will administer and review the medicine. Explain that an opioid is being used for analgesia, not because death is necessarily imminent.

For an opioid-naive adult with advanced progressive disease, NICE supports oral sustained-release morphine as maintenance when clearance is suitable, with immediate-release morphine for breakthrough. Its example starting range is 20 to 30 mg daily in divided sustained-release doses and 5 mg rescue. Frailty, low body weight, previous adverse effects or borderline clearance justify a lower starting plan and closer review. Significant renal or hepatic disease requires specialist input rather than copying this regimen.

Immediate-release titration is used in some services when pain is unstable or rapid dose finding is needed, but interval and supervision must follow the local palliative formulary. Sustained-release formulations should not be used as rescue. Once-daily, twice-daily and immediate-release products are not interchangeable by tablet count; prescribe generic drug, formulation, strength and timing unambiguously.

Titration uses response over a defined period. Review the previous 24 to 72 hours, separate spontaneous or incident breakthroughs, verify that rescue was taken correctly and assess toxicity. When continuous opioid-responsive pain remains and rescue is effective, incorporate a proportion of repeated requirement into maintenance, commonly increasing the regular daily total by roughly 30 to 50 percent. Larger changes, very high doses, rapid escalation or unclear response need specialist review.

Constipation prevention begins on day one unless diarrhoea or another contraindication is present. Nausea may occur transiently; offer an antiemetic when clinically indicated and search for other causes. Counsel about drowsiness, alcohol and sedatives, falls, driving law, safe storage away from children and visitors, not crushing modified-release products, and returning unused controlled drugs to a pharmacy.

Poor response requires reformulation, not endless dose increase. Review neuropathic pain, fracture, cord or nerve compression, retention, constipation, anxiety, non-adherence, end-dose failure, rapid disease change and opioid-induced hyperalgesia. Consider radiotherapy, intervention, adjuvant, route change or rotation with specialist support. Continue active reassessment even when the dose has no formal analgesic ceiling.

Key points

Confirm that pain is opioid responsive, moderate to severe and persistent enough to justify a strong opioid; address emergency and non-opioid mechanisms first.
First-line in advanced progressive disease is usually oral morphine when the oral route is reliable and renal and hepatic function are suitable.
NICE describes 20 to 30 mg total daily sustained-release oral morphine plus 5 mg immediate-release rescue during initial titration for a typical opioid-naive adult; use lower individual doses in frailty.
Prescribe a stimulant or osmotic laxative from initiation and give clear nausea advice; tolerance develops poorly to constipation.
Provide written scheduled dose, breakthrough dose, minimum interval, maximum action plan, storage, driving and toxicity instructions.
Review within days, not weeks, and after every increase. Count effective rescue doses and assess function, alertness, bowel habit, nausea and respiration.
If pain remains opioid responsive and adverse effects are acceptable, a common titration step is about 30 to 50 percent of the regular 24-hour dose, verified against local policy.
Do not increase automatically for incident pain, delirium, opioid-induced hyperalgesia, disease emergency or metabolite toxicity.
The gold standard is the lowest total dose that achieves the patient's functional goal with acceptable adverse effects, not a predetermined milligram target.

02Indications, selection and cautionsWho may benefit, who needs urgent treatment and important alternatives.

Suitable oral-morphine start

Persistent opioid-responsive pain, reliable swallowing, acceptable renal and hepatic function and capacity for safe administration support first-line oral titration.

Effective rescue response

A correctly timed immediate-release dose reduces the expected pain within its onset window without clinically important sedation or confusion.

Background under-treatment

Frequent spontaneous flares plus persistent baseline pain and reproducible rescue benefit may justify a proportionate maintenance increase.

Incident-pain pattern

Brief predictable flares with movement but comfortable rest may need pre-emptive rescue or structural treatment rather than higher continuous exposure.

Early adverse effects

Nausea, constipation, mild drowsiness and dry mouth require proactive management and review rather than automatic abandonment or unchecked continuation.

NeurotoxicityRed flag

New hallucination, cognitive fluctuation, myoclonus, hyperalgesia or excessive somnolence signals accumulation or interaction and blocks routine titration.

Red flags requiring action

New severe pain with neurological deficit, fracture, sepsis or obstruction needs cause-specific emergency management before routine titration.
Respiratory slowing, profound sedation, myoclonus, hallucinations or pinpoint pupils requires immediate toxicity assessment and dose withholding.
eGFR below 30 mL/min/1.73 m², rapidly changing renal function or severe hepatic impairment requires specialist or pharmacy-supported opioid selection.
Concurrent benzodiazepines, gabapentinoids, alcohol or illicit sedatives materially increase respiratory and falls risk.
Rapid repeated rescue use without relief may indicate an emergency, wrong mechanism, incident pain or unsafe self-administration rather than simple underdosing.
Uncontrolled access, diversion concern, cognitive impairment or an overwhelmed caregiver requires a supervised supply and administration plan.

03Assessment before treatmentTests and checks that guide safe selection.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
First-line opioid readiness assessmentFirst stepFirst line
Why
Confirm mechanism, severity, goal, current opioid exposure, oral reliability, organ function, cognition, sedatives and administration support.
Interpretation and limitations
Proceed only with a regimen whose route, starting dose and review intensity fit these risks; request specialist selection when clearance is impaired.
02
Baseline renal and hepatic function
Why
Identify reduced parent-drug or active-metabolite clearance before selecting morphine and deciding dose or interval.
Interpretation and limitations
Rapid clinical change matters more than an old stable result; eGFR below 30 or major hepatic impairment needs expert and formulary-guided choice.
03
Previous 24-hour opioid total
Why
Add all scheduled and administered breakthrough opioid by drug, route and formulation and account for recent switches.
Interpretation and limitations
This is essential for an opioid-experienced patient; never treat someone as opioid naive because their patch, liquid or rescue is missing from one chart.
04
Pain-pattern and rescue diary
Why
Record baseline pain, spontaneous and incident episodes, dose time, onset, duration, response and adverse effects.
Interpretation and limitations
Effective repeated rescue for persistent background pain supports titration; ineffective or trigger-specific dosing requires mechanism and kinetics review.
05
Sedation and respiratory assessment
Why
Measure arousability, cognition, respiratory rate and effort, oxygenation when indicated and concurrent central depressants.
Interpretation and limitations
Increasing sedation usually precedes serious respiratory toxicity; withhold and reassess rather than waiting for severe hypoventilation.
06
Bowel and nausea assessment
Why
Document baseline bowel frequency, obstruction risk, hydration, current laxatives, nausea mechanism and ability to retain oral medicines.
Interpretation and limitations
Constipation prophylaxis is routine, while vomiting, impaction or obstruction may require a different route and cause-specific treatment.

04Treatment approachPreparation, options, escalation and aftercare.

01Opioid-naive startInitiate oral morphine safelyFirst stepModerate-to-severe persistent pain is opioid responsive and oral morphine is suitable after assessment.

1Explain goals and risks, establish baseline cognition, breathing, bowel function and renal or hepatic status and remove duplicate opioid prescriptions.
2Use the NICE and local starting regimen adjusted for frailty, prescribe immediate-release rescue and laxative, and document nausea, driving, storage and emergency advice.
3Review pain, function, rescue response, alertness, respiration, nausea and bowel activity within a few days and sooner after concern.

02TitrationConvert response into a measured increaseContinuous pain remains unacceptable, rescue works and adverse effects are tolerable.

1Reconcile the actual previous 24 to 72 hours, separate incident episodes and confirm adherence, formulation, route and timing.
2Increase the regular 24-hour dose proportionately under the local palliative protocol, commonly by about 30 to 50 percent, and recalculate rescue coherently.
3Give the patient the new written schedule, remove superseded strengths where safe and reassess after steady exposure or earlier if sedation or poor relief occurs.

03Poor responseStop escalating and reformulateEscalationDose increases give little functional benefit, rescue fails or toxicity rises.

1EscalationWithhold further escalation and assess emergency pathology, neuropathic or mechanical pain, end-dose failure, adherence, interaction and opioid-induced hyperalgesia.
2Correct reversible drivers and seek specialist palliative or pain advice for rotation, route change, adjuvant, procedure or disease-directed therapy.
3Use close follow-up during any change, with explicit toxicity thresholds and a single reconciled prescriber-led plan.

04Care transitionPrevent controlled-drug discrepancyA titrating patient is discharged, admitted or transferred between prescribers and administration systems.

1Reconcile last administered doses, current total, rescue use, formulation, strength, supply, bowel plan and any discarded or returned stock.
2Communicate the clinical goal, titration rationale, next review and named prescriber to the receiving team and community pharmacy.
3Give the patient or caregiver one updated schedule, storage and contact advice and remove or clearly segregate obsolete formulations to reduce error.

05Regimens, contraindications and interactionsTreatment details and the circumstances that modify them.

Provides stable background analgesia for persistent moderate-to-severe opioid-responsive pain when the oral route and clearance are suitable.

Sustained-release oral morphine maintenance

NICE describes 20 to 30 mg total daily in divided sustained-release oral doses for a typical opioid-naive adult with advanced progressive disease, together with immediate-release rescue; start lower when frailty or sensitivity warrants and do not apply this regimen in significant renal impairment without expert advice.

Specify formulation and frequency, never crush modified-release preparations, check interactions and renal change and monitor sedation, respiration, cognition, nausea and constipation.

Treats breakthrough pain and provides response information used to adjust background therapy when episodes reflect continuous under-treatment.

Immediate-release oral morphine rescue

During initial titration NICE describes 5 mg oral immediate-release morphine as the rescue dose; later dosing must be recalculated from the current total daily opioid and verified under the local palliative formulary.

Do not confuse with sustained-release morphine, stack doses before onset, or use unchanged after renal deterioration or opioid conversion; repeated need demands clinical review.

Prevents or treats opioid-induced reduction in bowel motility, for which tolerance usually does not develop.

Senna constipation prophylaxis

A common adult starting regimen is senna 15 mg orally at night, titrated within the BNF and local protocol according to stool frequency and combined with an osmotic agent when needed.

Assess impaction and obstruction, hydration and diarrhoea; stimulant alone may be inadequate and persistent constipation needs examination rather than unlimited escalation.

Adds stool-softening and osmotic action when opioid constipation is present or stimulant prophylaxis is insufficient.

Macrogol osmotic laxative

Use one macrogol compound sachet orally daily initially and titrate, commonly to one to three sachets daily under the product, BNF and local regimen, with adequate fluid when feasible.

Review fluid tolerance, swallowing and obstruction; some products contain electrolytes and preparation volume may be difficult in advanced illness.

Provides prokinetic and antiemetic treatment while early opioid nausea settles or another cause is addressed.

Metoclopramide for selected opioid-related nausea

When gastric stasis or opioid-related nausea is suspected and no contraindication exists, a typical adult regimen is 10 mg orally or subcutaneously up to three times daily for a short reviewed course.

Avoid in complete bowel obstruction, Parkinson's disease or previous dystonia; use lower doses with renal impairment and limit duration because of extrapyramidal effects.

06Complications, monitoring and follow-upAdverse effects, response and longer-term review.

Arrange contact within a few days of initiation and after every titration, with same-day access for rising sedation or poor breathing.
Record pain pattern, chosen functional outcome and effective rescue count rather than accepting an unverified statement that tablets are not working.
Monitor arousability, respiratory rate and effort, cognition, hallucinations, myoclonus, falls and interaction with other sedatives.
Document bowel frequency, stool consistency, nausea, vomiting and adherence to prophylaxis at each early review.
Recheck renal and hepatic function after dehydration, sepsis, obstruction, cachectic decline or other change likely to alter clearance.
Review controlled-drug quantities, storage, driving, alcohol, caregiver administration and disposal during every care transition.
If three or more rescue doses are repeatedly needed in 24 hours, review the entire pain formulation and regimen rather than applying an automatic increase.

07Special situationsVariants, exceptions and circumstances that change the usual approach.

Morphine has no simple ceiling

Dose is limited by analgesic benefit and adverse effects, so lack of response should prompt reformulation rather than pursuit of a high number.

Sedation is an early warning

Increasing difficulty staying awake commonly appears before severe respiratory depression and should block the next routine increase.

Rescue use is diagnostic

Timing and response distinguish persistent under-treatment from incident pain, non-adherence, wrong mechanism and end-of-dose failure.

Constipation needs prevention

Waiting for impaction before prescribing a laxative creates avoidable pain, nausea, delirium and oral-route failure.

Formulation names matter

Immediate-release and modified-release products can contain the same opioid but have completely different safe uses and intervals.

A strong opioid is active care

Appropriate morphine can improve wakeful function and does not inherently signal abandonment or acceleration of death.

08Common pitfallsFrequent interpretation and management errors.

01
Starting morphine without checking renal function, sedatives and prior opioid exposure.
02
Prescribing a modified-release product as breakthrough treatment.
03
Giving no laxative or bowel-monitoring plan at initiation.
04
Increasing maintenance dose because of brief predictable incident pain.
05
Using reported tablet count without confirming formulation and strength.
06
Ignoring increasing drowsiness until respiratory rate becomes critically low.
07
Applying the standard NICE example unchanged to frailty or significant organ impairment.
08
Titrating repeatedly despite ineffective rescue and no functional improvement.
09
Allowing several teams to change controlled drugs without one reconciled plan.
10
Sending obsolete strengths home beside the new regimen without clear segregation.